Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
2011
423
LTM Revenue $67.6M
LTM EBITDA -$40.3M
$143M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sophia Genetics has a last 12-month revenue of $67.6M and a last 12-month EBITDA of -$40.3M.
In the most recent fiscal year, Sophia Genetics achieved revenue of $65.2M and an EBITDA of -$50.8M.
Sophia Genetics expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Sophia Genetics valuation multiples based on analyst estimatesFY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $62.4M | $65.2M | XXX | XXX | XXX |
Gross Profit | $31.3M | $42.9M | XXX | XXX | XXX |
Gross Margin | 50% | 66% | XXX | XXX | XXX |
EBITDA | -$69.6M | -$50.8M | XXX | XXX | XXX |
EBITDA Margin | -112% | -78% | XXX | XXX | XXX |
Net Profit | -$87.4M | -$79.0M | XXX | XXX | XXX |
Net Margin | -140% | -121% | XXX | XXX | XXX |
Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Sophia Genetics's stock price is $3.
Sophia Genetics has current market cap of $193M, and EV of $143M.
See Sophia Genetics trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$143M | $193M | XXX | XXX | XXX | XXX | $-0.91 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Sophia Genetics has market cap of $193M and EV of $143M.
Sophia Genetics's trades at 2.1x LTM EV/Revenue multiple, and -3.5x LTM EBITDA.
Analysts estimate Sophia Genetics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Sophia Genetics and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $143M | XXX | XXX | XXX |
EV/Revenue | 2.2x | XXX | XXX | XXX |
EV/EBITDA | -2.8x | XXX | XXX | XXX |
P/E | -3.1x | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | -2.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSophia Genetics's NTM/LTM revenue growth is 17%
Sophia Genetics's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.3M for the same period.
Over next 12 months, Sophia Genetics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Sophia Genetics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Sophia Genetics and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | 4% | XXX | XXX | XXX | XXX |
EBITDA Margin | -78% | XXX | XXX | XXX | XXX |
EBITDA Growth | -27% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | -61% | XXX | XXX | XXX | XXX |
Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
Opex per Employee | $0.3M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | 45% | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | 72% | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | 53% | XXX | XXX | XXX | XXX |
Opex to Revenue | 170% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Beamtree | XXX | XXX | XXX | XXX | XXX | XXX |
Cogstate | XXX | XXX | XXX | XXX | XXX | XXX |
Echo IQ | XXX | XXX | XXX | XXX | XXX | XXX |
Impedimed | XXX | XXX | XXX | XXX | XXX | XXX |
Proteomics International | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sophia Genetics acquired XXX companies to date.
Last acquisition by Sophia Genetics was XXXXXXXX, XXXXX XXXXX XXXXXX . Sophia Genetics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Sophia Genetics founded? | Sophia Genetics was founded in 2011. |
Where is Sophia Genetics headquartered? | Sophia Genetics is headquartered in United States of America. |
How many employees does Sophia Genetics have? | As of today, Sophia Genetics has 423 employees. |
Who is the CEO of Sophia Genetics? | Sophia Genetics's CEO is Dr. Jurgi Camblong, M.B.A.,PhD. |
Is Sophia Genetics publicy listed? | Yes, Sophia Genetics is a public company listed on NAS. |
What is the stock symbol of Sophia Genetics? | Sophia Genetics trades under SOPH ticker. |
When did Sophia Genetics go public? | Sophia Genetics went public in 2021. |
Who are competitors of Sophia Genetics? | Similar companies to Sophia Genetics include e.g. Beamtree, Cogstate, Echo IQ, Impedimed. |
What is the current market cap of Sophia Genetics? | Sophia Genetics's current market cap is $193M |
What is the current revenue of Sophia Genetics? | Sophia Genetics's last 12-month revenue is $67.6M. |
What is the current EBITDA of Sophia Genetics? | Sophia Genetics's last 12-month EBITDA is -$40.3M. |
What is the current EV/Revenue multiple of Sophia Genetics? | Current revenue multiple of Sophia Genetics is 2.1x. |
What is the current EV/EBITDA multiple of Sophia Genetics? | Current EBITDA multiple of Sophia Genetics is -3.5x. |
What is the current revenue growth of Sophia Genetics? | Sophia Genetics revenue growth between 2023 and 2024 was 4%. |
Is Sophia Genetics profitable? | Yes, Sophia Genetics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.